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Although a number of drugs have been developed and approved to combat HIV over the 
past 40 years, mutations of the virus and its protein targets have necessitated the continued 
discovery and design of even more novel compounds today. In the Fuchs lab, we are 
approaching this problem by targeting an allosteric binding site on HIV-1 integrase, an integral 
enzyme that is responsible for integrating the viral genome into the host’s DNA. This allosteric 
site is the same binding site as that used by the cofactor LEDGF/p75, a host cell protein that 
promotes the activity of integrase. Binding of small molecule drugs at this allosteric binding site 
along the CCD dimer interface of integrase results in the inactivation of the protein due to the 
formation of aberrant integrase multimers. This hyper-multimerization occurs as a result of 
interaction of the CTD subunit of another integrase protein with the CCD dimer interface. We 
are currently synthesizing new inhibitors based on a well-studied quinoline core scaffold and 
scaffold hoping to an indole core scaffold. The indole core scaffold was chosen due to the 
existence of well-established synthetic routes and the ease of functionalization of the indole core. 
In addition, the tilt of aromatic ring in the allosteric binding pocket has been hypothesized to 
improve binding of the compounds in the presence of known mutations, namely the A128T 
mutation. Inhibitors of this type are also structurally unique and may lead to the development of 
new intellectual property. The ultimate goal of these studies is to develop compounds with 
greater intregrase inhibitory activity through binding to the LEDGF/p75 site than previously 
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Introduction to HIV and HIV Therapy 
 Human immunodeficiency virus (HIV) affects approximately 37.9 million people 
worldwide. In 2017 alone, HIV led to over 1 million autoimmune deficiency (AIDs) related 
deaths1. Since the rapid emergence of this retrovirus in the late-twentieth century, significant 
research efforts have led to a better understanding of HIV and the etiology of the symptoms it 
induces. The study of the biology of HIV and the viral life cycle (Figure 1) has paved the way for 
the development of therapeutics to prevent or treat the disease by rendering the continuation of 
the viral life cycle infeasible2.  
 
Figure 1. The viral life cycle of HIV and potential drug targets2 
 Interestingly, HIV only encodes 15 proteins, many of which have become important 
targets in the fight against this disease. By studying the role and structure of these unique protein 
targets, a variety of therapeutic approaches have been implemented to specifically affect viral 
fitness and infectivity, and thereby generate effective treatments. Fusion inhibitors, for example, 
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block the fusion of the virus to the host’s cell membrane. Similarly, chemokine receptor type 5 
(CCR5) antagonists are used to block the CCR5 co-receptor on the surface of immune cells to 
prevent the virus from entering (AIDS Info). Nucleotide/nucleoside reverse transcriptase 
inhibitors (NRTIs) function as chain terminators to block extension of the viral DNA chain 
during reverse transcription (Immunopaedia) and integrase inhibitors (INISs) impair the 
integration step by binding to the active site of integrase thus inhibiting the viral DNA’s ability 
to integrate itself into the host DNA. Currently, each of these mechanisms for combating HIV 
are utilized in currently available FDA-approved therapeutic drugs. A list of the individual HIV 
drugs “recommended for the treatment of HIV in the United States based on the U.S. Department 
of Health and Human Services HIV/AIDS medical practice guidelines” is included in Table 1.  
Drug Name Drug Class Drug Name Drug Class Drug Name Drug Class 
Abacavir NRTI Etravirine NNRTI Saquinavir PI 
Emtricitabine NRTI Nevirapine NNRTI Tipranavir PI 
Lamivudine NRTI Rilpivirine NNRTI Enfuvirtide Fusion inhibitor 
Tenofovir DF NRTI Atazanavir PI Maraviroc CCR5 antagonist 
Zidovudine NRTI Darunavir PI Raltegravir Integrase inhibitor 
Doravirine NNRTI Fosamprenavir PI Dolutegravir Integrase inhibitor 
Efavirenz NNRTI Ritonavir PI Ibalizumab-
uiyk 
Post-attachment  
Table 1. Recommended drugs for the treatment of HIV infections according to the U.S. 
Department of Health and Human Services. Abbreviations for drug classes: NRTI = Nucleoside 
Reverse Transcriptase Inhibitor; NNRTI = Non-nucleoside Reverse Transcriptase Inhibitor; PI = 







 Highly active antiretroviral therapy (HAART) is a term that describes treatment of 
patients using a cocktail of three different drugs that act on different targets of the HIV-1 
lifecycle. Prior to HAART, the common treatment of antiretroviral cases were mono or 
combination therapies using two different antiretroviral compounds. This form of therapy 
resulted in limited success in treatment of HIV and failed to suppress viral activity. With the 
introduction of protease inhibitors in the 1990s, it became possible to administer a combination 
of three separate drug agents to overcome the rapid emergence of resistance to a single agent. 
This new form of combination therapy for retroviruses showed efficient suppression of viral 
activity by stopping the lifecycle at different points. This multi-drug therapy has been coined 
“triple therapy” due to the three active drugs consisting of entry inhibitors, nucleoside inhibitors, 
non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, and/or protease inhibitors3. 
HIV-1 Integrase as a Target for Drug Development 
HIV-1 integrase is one of “newest” targets of the approved HIV drugs in terms of FDA 
approval dates. This enzyme is responsible for the critical integration of the viral DNA into the 
host DNA in a two-step reaction. In the first step, IN removes the two terminal nucleotides (G 
and T) from each 3’ end of the double-stranded viral DNA. “Joining” or “strand transfer” is the 
second step, which consists of a Sn2 nucleophilic attack by the free 3’ hydroxyl group on the 
viral DNA to the host cell’s chromosomal DNA producing two joined molecules4,5. The strand 
transfer process is then completed by cellular DNA repair mechanisms that fills any gaps 




Figure 2. Mechanism of HIV-1 integrase8 
HIV-1 IN is made up of 288 amino acid residues, which are the building blocks for the 
three domains: the N-terminal domain (NTD), the catalytic core domain (CCD), and the C-
terminal domain (CTD). Together these three domains make up a single IN protein or monomer. 
In the NTD, two histidine and cysteine residues form a HHCC zinc-finger motif which chelates a 
zinc atom in each monomer. This motif ultimately facilitates the formation of a tetramer (or 
higher order oligomer) through multimerization of the IN monomers. The tetramer is believed to 
be required for IN activity, since it is necessary for DNA binding and the subsequent strand 
transfer reactions. Through this integration process, the viral DNA is successfully incorporated 
into the host genome, enabling the formation and maturation of additional viral particles8. 
 Of particular interest for the treatment of HIV is the targeting of the viral life cycle at the 
integration stage. INISs are one class of HIV drugs that accomplish this through binding to the 
active site of IN. Raltegravir was the first member of this class to make it to the market, 
receiving approval in 2007. Dolutegravir was introduced six years later, but has a much higher 
barrier to resistance than raltegravir. Elvitegravir and Bictavir are also INIS drugs prescribed in 
conjunction with other treatments for the management of HIV. All of these INISs contain a 
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similar central pharmacophore that interacts with the two magnesium (or manganese) ions in the 
integrase active site. However, frequent aberrant mutations of the viral genome have begun to 
render the efficacy of these current treatment options sub-therapeutic, suggesting the need to 
















































































 One form of INIS that has been studied more recently is the allosteric integrase inhibitors 
(ALLINIs). These compounds have been shown to bind outside of the active site of integrase in 
the same pocket as the natural cofactor LEDGF/p75 at the CCD dimer interface. Binding of 
small molecules at this allosteric site results in the inactivation of integrase due to the formation 
of aberrant integrase multimers. This hyper-multimerization occurs as a result of interaction of 
the CTD subunit of another integrase protein with the CDD dimer interface. It is hypothesized 
that while these small molecules do not directly compete with the natural cofactor, the induction 
of multimers of integrase through binding of the ALLINI after the natural ligand is no longer 
bound results in a malformation of the packaging of the viral load, thereby rendering the new 
virus noninfectious9. One such small molecule, BI224436 by Gilead Science, advanced to phase 
one clinical trials, but failed to provide the necessary safety profile for continued development. 
Currently, no FDA-approved small molecules for the treatment of HIV that target the allosteric 
site of integrase are on the market8.  
Quinoline scaffold 
 Previous studies had discovered that small molecules can target the LEDGF/p75 binding 
site and disrupt IN binding, thus halting the integration process. This led Debyser and coworkers 
to rationally design a high throughput screening that ultimately resulted in the discovery of a 
series of 2-(quinoline-3-yl) acetic acid derivatives that act as inhibitors of the LEDGF/p75- 
integrase interaction10.  These screenings started with a limited set of 20,000 commercially 
available compounds to establish a pharmacophore. In silico screening of these compounds 
produced 2,000 hits after two passes. From these 2000 hits, the top 25 compounds which scored 
the best in this simulation were selected for biological testing resulting in one hit compound 
(LEDGIN-1). Multiple rounds of structure-activity refinement produced a highly potent 2-
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(quinoline-3-yl) acetic acid analog (LEDGIN-6). This analog was reported to be ten times more 
potent (IC50= 1.37 µM) against IN-LEDGF/p75 interactions in vivo while exhibiting a reported 
twenty-fold increase in antiviral activity (EC50= 2.35 µM) over other studied quinoline acidic 
acids11.  
MOA of Quinoline ALLINIs 
 Previous members of the Fuchs lab initially synthesized several of the early quinoline-
based ALLINIs to study their biological profiles. Among the compounds synthesized were 
LEDGIN-6 and BI-1001, both of which were previously reported by the Debyser lab and 
Boehringer Ingelheim, respectively11,12. LEDGN-6 and BI-1001 were evaluated by the 
Kvaratskhelia lab using homogeneous time resolved fluorescence (HTRF)-based IN-LEDGF/p75 
binding assays. These studies revealed that both compounds have identical modes of actions and 
similar IC50 values when inhibiting IN-LEDGF/p75. Determination of IC50 values and 
mechanism of action used a 3’ processing and strand transfer activity assay to measure 
LEDGF/p75 independent inhibition. The 3’ processing assay showed that LEDGIN-6 and BI-
1001 inhibited integrase activity with IC50 values of 3.9 and 2.3 µM, respectively. Stand transfer 
assays reported that LEDGN-6 inhibited stand transfer with an IC50 value of 4.2 µM and 1.7µM, 
respectively. The kd values obtained from these experiments for LEDGN-6 and BI-1001 were 
10.0 and 1.0 µM, respectively. These quinoline structures were also observed to promote 
aberrant multimerization of IN. The term “aberrant IN multimerization” refers to the formation 
of inactive IN oligomers that vary from the correctly assembled tetramer. LEDGIN-6 and BI-
1001 induced this aberrant multimerization with IC50 values of 11.3 and 4.9 µM, respectively. 
Lastly, the anti-viral activity for LEDGN-6 and BI-1001 were 12.2 and 5.8 µM respectively12. In 
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the head-to-head comparison of these compounds, BI-1001 showed very slightly better potency 
than LEDGN-6 in the various assays8. 
 
Figure 4. Chemical structures of BI-1001 and LEDGIN-6. 
 Crystal structure analysis of BI-1001 bound to the CCD dimer interface of IN indicated 
that the carboxylic acid moiety of the compound hydrogen bonds with histidine-171 (H171) and 
glutamate-170 (E170). Additionally, the α-methoxy group on BI-1001 shows an additional 
interaction through hydrogen bonding with threonine-174 (T174) which is hypothesized to be the 
reason that it shows a better potency than LEDGN-6. Both LEDGN-6 and BI-1001 express 
multimodal mechanisms of action, each leading to the inhibition of LEDGF-IN binding in 




Figure 5. The formation of aberrant mutlimerization of IN in the presence of ALLINIs 
Resistance Mechanism 
 One of the main drivers of the necessity of novel targets and compounds to treat HIV is 
the frequent and aberrant mutations leading to resistance to many of the current compounds 
being used or tested as therapies. During the course of HIV drug development, resistance 
mutations to drugs are deliberately developed in order to study the escape mechanisms employed 
by the virus. Dr. Kvaratskhelia’s group has studied one mutation in particular, A128T, which 
was developed upon treatment with these prototypical ALLINIs. A128T is located in the IN-
dimer interface where LEDGF/p75 or ALLINIs would occupy. It is hypothesized that this 
resistance is due to a shift of the quinolone core downwards in the binding pocket due to the 




Scaffold hopping to indole 
 The A128T resistance mutation pushed the necessity to discover novel allosteric 
integrase inhibitors. Scaffold hopping techniques were employed to assist in developing new 
compounds. The term “Scaffold Hopping” refers to the method of functionalizing groups around 
a central core. Scaffold hopping techniques have been used for many reasons including i) 
replacement of a lipophilic scaffold by a more polar one, ii) substitution of a metabolically labile 
scaffold with a more stable or less toxic one, and iii) replacement of a very flexible scaffold with 
a rigid central core8. 
 Scaffold hoping was employed as a part of this project to discover novel allosteric IN 
inhibitors using the already established quinoline-based compounds as a reference core. 
Numerous heterocyclic compounds have been employed or considered by the Fuchs lab as 
potential core structures including pyridine, thiophene, isoquinoline, and indole cores. As a part 
of these studies, the indole scaffold was employed as a candidate for further ALLINI 
development for three reasons. These reasons being: 1) a wide variety of established synthetic 
routes were available to ease of development of these biologically active compounds, 2) the 
innate reactivity of the indole core which allows ease of functional group additions, and 3) the 
limited patent coverage of the indole core being used a ALLINIs leaving room for the 
development of novel intellectual property8, 13. The goal using this approach was to explore the 
differences in binding, geometry, electronics, and hydrogen bonding effects of the electron rich 
indole core against the electron deficient quinoline core.  
 Before synthesis on the indole scaffold began, computational models developed by Guqin 
Shi in Dr. Chenglong Li’s lab using AutoDock 4.0 were used to predict possible binding modes 
of the indole core. This prediction was necessary due to the difference in size between the highly 
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substituted five membered pyrrole-like ring of the indole as compared to the six membered 
pyridine-like ring of the quinolone system. Although the indole ring system has a different shape 
then the quinoline scaffold, the binding modes for these scaffolds were found to be maintained. 
According to docking studies, the pharmacophoric acetic acid and aryl groups overlay in the 
same areas of space as seen in quinoline binding. The major difference between the two 
molecules is the scaffold positioning itself. As the acid side chain anchors the molecule in the 
pocket, the smaller size of the five membered ring of the indole necessitates a slight tilt in the 
opposite direction of the A128T residue which previously was the means of resistance to the 
quinoline-based ALLINIs. With these results, it was established that the indole scaffold should 
be pursued in the synthesis of ALLINI analogs8.  
 
Figure 6. A docking model BI-1001 (purple) and a first-generation indole analog (white) in the 




Strategies for the Optimization of the Indole Scaffold 
 When trying to develop a strategy for the design and synthesis of novel indole scaffolds 
of ALLINIs, the positions of the key pharmacophoric groups being transferred from the 
quinolone needed to be considered. Since the primary ring of the indole is smaller than that of 
the quinolone, the positioning of these substituents as well as the consideration for further 
synthetic manipulation was confirmed through comparison of docking models with the quinoline 
crystal structures. Perhaps the most important group on the indole scaffold is the carboxylic acid 
side chain that is attached at the C2 position of the indole nucleus (which is adjacent to the N 
atom on the C2 carbon of the pyrrole-like ring). This group is necessary for the direct binding to 
the IN protein and has been stated to be “critical for antiviral potency and that there was no 
tolerated isosteric replacement for the acid” (Fader et al.)14. With the acid in place, the only 
possible areas for modifications off the indole ring are the N1, C5, C6, and C3 positions (based 










Figure 7. A structural map of sites for possible modifications on the indole scaffold 
 The N1 and C3 positions would initially be held mostly constant with a methyl at the C3 
position and an anisole or chromane ring at N1. With this is mind, the C5 and C6 positions were 
targeted first for optimization. This strategy served two primary pursposes: 1) no previous 
findings of indole-based ALLINIs had been optimized at the C5 and C6 positions and 2) the 
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introduction a solvent facing group would be expected to interact with subunit 1 in the IN-CCD 
dimer interface causing a disruption in protein formation. With regard to the C3 or N1 position, 
depending on which starting material is used, the position would be largely unchanged from the 
general hydrophobic group of an anisole or chromane group occupying the position for 
hydrophobic interactions.  
 The synthetic route that was chosen to be used was the addition of the hydrophobic 
chromane or anisole at the N1 position and optimization at the C5 position. This was chosen in 
analogy to the previous studies on the novel ALLINI KF116 that showed that having the solvent 
exposed groups being positioned in the “lower left quadrant” of the molecule presented a greater 
binding affinity. With this, the synthetic route was optimized using the N1 group as the anchor 
for the hydrophobic group for binding to the CCD dimer interface.  
1.7 1.8  
Figure 8. Comparison of the proposed indole compounds (1.7) to KF-116 (1.8). 
 
Synthesis of C5 substituted indoles 
  The synthesis of the substituted indole series began with the commercially available 3-
methyl indole, which was then subjected to an Ullmann coupling15 reaction with either an anisole 
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or chromane moiety. These rings served as the hydrophilic/aromatic groups that would project 
from the N1 position of the indole of the molecule into a narrow, capped hydrophobic channel in 
the dimer interface. Next the keto-ester side chain was added via the conditions shown in Figure 
8. The keto-ester group would require subsequent functionalization to produce the biologically 
active acetic acid side chain. Once the keto-ester was established, however, the C5 position of 
the indole was brominated, via the conditions in Figure 8. To add the sterically bulky t-butyl 
group to the keto-ester side chain, the ketone was reduced to an alcohol using sodium 
borohydride, yielding an alcohol. After purification of the resulting alcohol, the t-butyl group 
was attached using t-buOAc/perchloric acid to yield the desired “Key Intermediate” product. 
From this intermediate, substitutions of the previously established C5 bromine using Suzuki 
coupling methods were employed to yield derivatives of the original indole scaffold. Upon 
successful coupling at the C5 position, the ester group on the C2 position could be saponified to 
produce the carboxylic acid that would be subjected to biological testing. 
 




The t-butyl ether represents a point of divergence in the synthetic route, potentially 
facilitating the production of a number of diverse substrates. At this point, the brominated C5 
position allows for the customization and optimization of the compound through the addition of 
different functional groups via a Suzuki reaction using various boronic acid reagents. The main 
goal of these newly added functional groups is to point away from the IN-CCD binding area in 
hopes of picking up interactions with the incoming CTD subunit to efficiently promote 
multimerization and thus effective IN inhibition. 
 Though the ALLINIs based on the indole scaffold are still a relatively novel potential 
drug class, several compounds have been previously synthesized in the Fuchs lab by Dr. Janet 
Antwi. Many of the tested compounds that were produced consisted of an anisole residing on the 
N1 position of the scaffold while the carboxylic acid chain remained on the C2 position to ensure 
biological activity. Different functional groups were added via Suzuki coupling reactions and 
biological data of some her most potent compounds can been seen in Table (2) along with 
structures of each respective compound.  
 Dr. Antwi’s compounds were tested in the Kvaratshelia lab using a LEDGF/p75 
independent assay. For clarification, this particular assay was run without LEDGF/p75, while 
dependent assays are run in the presence of LEDGF/p75. The assay itself was designed to mimic 
the stage in the HIV-1 where LEDGF/p75 is no longer present after the integration phase has 
already finished. Instead of measuring the direct inhibition of the ALLINI against LEGDF/p75, 
the assay determines the direct effect of the drug on IN, ultimately leading to aberrant multimer 
formation of the IN enzyme. These aberrant multimers of IN are the inactive form of the IN 
enzyme and can no longer continue the life cycle of the virus.  
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 My initial work in the Fuchs lab focused on the synthesis of the bromide in an effort to 
prepare novel ALLINIs. Utilizing the methods established by Dr. Antwi, I was able to repeat and 
troubleshoot these synthetic steps to produce the desired product. With this intermediate in hand, 
it was coupled to a thiphene to produce a new ALLINI compound. Upon purification and 








 In addition to the introduction of the anisole ring on the N1 position, other ring systems, 
including the chromane system, have been shown to possess even greater potency against IN in 
other series of ALLINI analogues. The attachment of the anisole itself was initially chosen for 
the known hydrophobic characteristics that it possesses, but also for the ease of synthesis of the 
anisole-indole intermediate due to iodo-anisole (a reagent for Ullman coupling of the anisole to 
the 3-methyl indole) is commercially available. It is hypothesized that substituting the anisole 
ring with a more hydrophobic functional group would increase the binding affinity into the 
allosteric site of IN. The chromane derivatives, therefore, were expected to provide better 
potency, but the chemistry necessary for their introduction was not as well established. 
 
Figure 10. Synthetic scheme of chromane substituted indole based on anisole indole synthesis 
 As previously mentioned, the reagent, 4-iodo-chromane, to synthesize the chromane 
indole intermediate is not commercially available. This inconvenience required the synthesis of 
the necessary starting material in a two-step reaction. 4-chromanone was reduced using Zn dust 
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in acetic acid yielding chromane. The chromane was then subjected to a halogenation reaction in 
the presence of I2 and AgNO3 yielding 4-iodo-chromane. 4-iodo-chromane was subjected to an 
Ullmann coupling reaction in the presence of 3-methyl-indole to yield the chromane substituted 
indole on the N1 position. To establish the keto-ester on the C2 of the scaffold, the conditions 
represented in figure (9). To establish the t-butyl ester, the keto-ester was reduced using sodium 
borohydride yielding the alcohol. Finally, treatment with t-BuOAc/perchloric acid provided the 
desired “Key Intermediate” product. 
 Having successfully completed the synthesis of an anisole derivative, I was also able to 
carry out the synthesis of the more synthetically challenging chromane. This synthesis was 
important not only to generate more of the key intermediate for analogue synthesis, but also to 
produce all of the synthetic intermediates in sufficient quantity and purity for chemical 
characterization. With this synthesis in hand, therefore, all of the intermediates in this sequence 
were characterized using 1H NMR, 13NMR, and HRMS. The bromide intermediate was also 
saponified to generate a new analogue for testing. This compound has also been submitted to Dr. 
Larue for testing. Subsequent efforts will be focused on the derivatization of this bromide in an 
effort to introduce substituted aromatic rings onto this chromane-containing indole system. It is 
expected that the introduction of the most potent aromatic systems in Dr. Antwi’s studies with 
the anisole system into the chromane series will produce compounds with higher potency for 


























1.20. To a solution of 3-methyl indole (306.5 mg, 2.34 mmol) in DMSO (0.25 M), was added 
iodochromane (650 mg, 2.5 mmol), CuI (44mg, 0.231 mmol), K3PO4 (989.18 mg, 4.66 mmol), 
and benzotriazle (111.38 mg, 0.935 mmol). The mixture was heated to 120 °C and stirred 
overnight. Upon completion, the reaction mixture was quenched with water and extracted with 
ethyl acetate (3x) and evaporated under reduced pressure. The crude mixture was washed with 
water, brine, dried over sodium sulfate and concentrated under educed pressure. Flash 
chromatography (silica gel, 1-2% ethyl acetate in hexanes) yielded the coupled product as a 
bright pink oil. 1H NMR (400 MHz, CDCl3). δ 7.67 (d, J = 7.5 Hz, 1H), 7.51 (d, J = 7.5 Hz, 1H), 
7.32-7.17 (m, 4H), 7.10 (s,1H), 6.95 (d, J = 8.7 Hz, 1H), 4.32-4.28 (m, 2H), 2.88 (t, J = 6.5 Hz, 
2H), 2.44 (s, 3H), 2.06-2.12 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 153.34, 136.47, 132.49, 
129.36, 125.96, 125.77, 123.64, 123.14, 122.08, 119.41, 119.09, 117.54, 111.94, 110.34, 66.63, 
31.67, 25.06, 22.25, 9.63. 
 
1.21. To a solution of indole-chromane (598 mg, 2.27 mmol) in toluene (11.4 ml, 0.20 M) was 
added oxalyl chloride (1.8ml, 20.4mmol). The resulting mixture was heated to 75 °C and stirred 
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overnight. Upon completion, the mixture was cooled to 0 °C and methanol (34ml, 60% M) was 
slowly added while stirring. The solution was then concentrated under reduced pressure and 
taken back up in EtOAc. The organic layer was washed with sat. NaHCO3 solution (2x). The 
combined aqueous layers were washed with EtOAc. The combined organic layers were 
vigorously washed with water (5x), brine (1x), dried over sodium sulfate, and concentrated under 
reduced pressure. Flash chromatography (silica gel, 10% EtOAc in hexanes) yielded product as 
yellow oil. 1H NMR (400 MHz, CDCl3). δ 7.77 (d, J = 8.1 Hz, 1H), 7.37 (t, J = 7.7 Hz, 1H), 7.21 
(d, J = 7.3 Hz, 1H), 7.18 (d, J = 8.5 Hz, 1H), 7.10 (dd, J = 8.6 Hz, 1H), 6.99 (d, J = 2.5 Hz, 1H), 
6.92 (d, J = 8.6, 1H), 4.30-4.21 (m, 2H), 3.56 (s, 3H), 2.81 (t, J = 6.5 Hz, 2H), 2.64 (s, 3H), 2.04 
(qd, J = 6.3, 4.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 179.72, 164.38, 154.63, 140.46,130.58, 
129.58, 129.35, 127.61, 127.38, 126.91, 126.29, 123.03, 121.41, 121.11, 117.46, 111.53, 66.66, 
52.42, 24.83, 22.07, 10.37.  
 
1.22. To a solution of indole-chromane keto-ester (156 mg, 0.45 mmol) in DCM (4.5ml, 0.10 M) 
was added freshly recrystallized NBS (87.4 mg, 0.5 mmol) and acetic acid (28 µL, 0.5 mmol). 
The mixture was stirred at 60 °C for 30 minutes. Upon completion, the reaction was quenched 
with water and extracted with DCM (3x). The combined layers were washed with water, brine, 
dried over sodium sulfate, and concentrated under reduced pressure. Flash chromatography 
(silica gel, 10% EtOAc, 15% DCM, in hexanes) afforded the brominated product as a yellow oil. 
1H NMR (400 MHz, CDCl3). δ 7.87 (dd, J = 1.9, 0.7 Hz, 1H), 7.40 (dd, J = 8.9, 1.9 Hz, 1H), 
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7.06 – 7.02 (m, 2H), 6.94 (d, J = 2.7 Hz, 1H), 6.89 (d, J = 8.6 Hz, 1H), 4.28 – 4.22 (m, 2H), 3.55 
(s, 3H), 2.81 (t, J = 6.4 Hz, 2H), 2.58 (s, 3H), 2.04 (p, J = 6.2 Hz, 2H). 13C NMR (101 MHz, 
CDCl3) δ 179.64, 164.00, 154.91, 138.81, 131.30, 130.37, 129.19, 129.02, 128.87, 126.76, 
124.86, 123.76, 123.16, 117.58, 114.24, 113.13.  
 
1.23. Brominated chromane-indole (122 mg, 0.29 mmol) was taken up in a 4:1 mixture of 
THF:EtOH (0.1 M total) and cooled to 0 °C. NaBH4 (11 mg, 0.29 mmol) was added slowly 
added and stirred at 0 °C for 1h. The reaction was quenched with a slow addition of water. The 
aqueous solution was extracted with EtOAc (3x). The combined organic layers were washed 
with brine, dried over sodium sulfate, and concentrated under reduced pressure. Flash 
chromatography (silica gel, 20% EtOAc, in hexanes) afforded the reduced product. 1H NMR 
(400 MHz, CDCl3). δ 7.72 (d, J = 1.9 Hz, 1H), 7.22 (dd, J = 8.7, 1.9 Hz, 1H), 7.14 (dt, J = 8.3, 
2.1 Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 6.90 (dd, J = 9.5, 5.7 Hz, 2H), 5.25 (dd, J = 13.9, 3.4 Hz, 
1H), 4.26 (dd, J = 5.9, 4.3 Hz, 2H), 3.69 (d, J = 12.2 Hz, 3H), 3.31 (t, J = 5.0 Hz, 1H), 2.82 (q, J 




1.24. Hydroxyester chromane-indole (70.6 mg, 0.164 mmol) was dissolved in t-BuOAc (3.28 ml, 
0.05 M) and cooled to -22 °C. Perchloric acid (0.38 ml, 0.437 M) was added to the solution and 
was stirred. Every 20 minutes the solution was monitored by TLC for the presence of an 
undesired byproduct. Upon the formation of the undesired product, the solution was quenched 
with Na2CO3. The aqueous layer was extracted with EtOAc (3x), washed with brine, dried over 
sodium sulfate, and concentrated under reduced pressure. The crude material was purified by 
flash column chromatography (silica gel, 10% EtOAc, in hexanes) to afford t-butyl ether. 1H 
NMR (400 MHz, CDCl3). δ 7.70 (d, J = 1.9 Hz, 1H), 7.18 (dt, J = 9.4, 2.7 Hz, 2H), 7.00 – 6.84 
(m, 3H), 5.08 (s, 1H), 4.27 (t, J = 5.2 Hz, 2H), 3.64 (d, J = 1.8 Hz, 3H), 2.84 (q, J = 6.6 Hz, 2H), 
2.38 (d, J = 2.4 Hz, 3H), 2.07 (dt, J = 8.5, 3.7 Hz, 2H), 1.08 (d, J = 4.9 Hz, 9H). 13C NMR (101 
MHz, CDCl3) δ 171.52, 154.95, 136.69, 134.78, 131.16, 130.09, 129.78, 129.01, 128.55, 127.36, 
124.99, 122.88, 121.39, 117.32, 112.77112.11, 110.44, 75.79, 66.68, 66.51, 52.21, 27.90, 24.84, 
22.08, 8.72. 
 
1.25. To a solution of chromane-indole (1 equiv) in a 1:1 mixture of THF (0.1 M) and MeOH 
(0.1 M) was added 3N NaOH solution (5 equiv). The resulting solution was then stirred at rt 
overnight until completion. The reaction was quenched with water and 2N HCl was slowly 
added to reach a pH of ≈ 4. The aqueous layer was then extracted with EtOAc (3x). The 
combined organic layers were washed with water, brine, dried over sodium sulfate, and 
concentrated under reduced pressure. The resulting acid was triturated with hexanes to afford the 
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desired product. 1H NMR (400 MHz, CDCl3). δ 7.70 (d, J = 1.9 Hz, 1H), 7.28 – 7.18 (m, 2H), 
7.01 (dd, J = 8.5, 2.6 Hz, 1H), 6.96 – 6.85 (m, 2H), 5.16 (d, J = 22.6 Hz, 1H), 4.26 (q, J = 4.2, 
3.7 Hz, 2H), 2.81 (dt, J = 15.5, 6.5 Hz, 2H), 2.36 (d, J = 6.0 Hz, 3H), 2.06 (d, J = 12.3 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 171.09, 155.07, 136.96, 136.79, 133.68, 131.22, 129.83, 129.73, 
129.59, 128.77, 128.72, 128.60, 127.29, 125.48, 125.40, 123.30, 123.03, 121.50, 121.46, 117.46, 
117.36, 112.99, 112.92, 112.15, 112.12, 110.77, 110.50, 66.73, 66.21,65.99, 28.02. 24.94, 24.83, 
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